insights_auto
Outlook: 76.5% bullish·5.9% bearish
Go to analysischevron_right
REGN34:BVMF
Regeneron Pharmaceuticals Inc BDR
R$63.78
arrow_downward
-1.39%(-0.90) 1D
Oct 2, 4:56:00 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN34...
Open
R$64.38
High
R$64.38
Low
R$63.66
Mkt. cap
75.69B
Avg. vol.
608.00
Volume
6.82K
52-wk high
R$73.13
52-wk low
R$49.47
Shares outstanding
101.14M
No. of employees
15K
Open
R$64.38
High
R$64.38
Low
R$63.66
Mkt. cap
75.69B
Avg. vol.
608.00
Volume
6.82K
52-wk high
R$73.13
52-wk low
R$49.47
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
Simply Wall Street
·
21 hours ago
Regeneron (REGN) Stock May Be Underpriced Despite Its $1b Alliance Expansion
Investing.com
·
1 day ago
Baird reiterates Regeneron stock rating on Sanofi collaboration
Investing.com
·
1 day ago
Jefferies raises Regeneron stock price target to $930 on partnership
StockStory
·
1 day ago
Why Regeneron (REGN) Stock Is Trading Lower Today
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc BDR
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 3.75B | 3.88B | 3.61B | 4.29B |
Cost of goods sold | 2.00B | 2.21B | 2.21B | 2.21B |
Cost of revenue | 2.00B | 2.21B | 2.21B | 2.21B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 657.80M | 775.00M | 647.70M | 662.10M |
Operating expense | 647.80M | 775.00M | 647.70M | 662.10M |
Total operating expenses | 2.64B | 2.99B | 2.86B | 2.87B |
Operating income | 1.11B | 898.60M | 744.80M | 1.42B |
Other non operating income | 3.00M | 958.50M | -7.30M | 100.00K |
EBT including unusual items | 1.76B | 1.04B | 831.20M | 1.53B |
EBT excluding unusual items | 1.27B | 2.04B | 908.10M | 1.59B |
Income tax expense | 303.30M | 199.10M | 104.00M | 230.90M |
Effective tax rate | 17.20% | 19.08% | 12.51% | 15.11% |
Other operating expenses | -10.00M | - | - | - |
Net income | 1.46B | 844.60M | 727.20M | 1.30B |
Net profit margin | 38.89% | 21.74% | 20.17% | 30.23% |
Earnings per share | 11.83 | 11.44 | 9.47 | 14.29 |
Interest and investment income | 175.10M | 193.30M | 183.50M | 183.30M |
Interest expense | -19.30M | -12.20M | -12.90M | -11.00M |
Net interest expenses | 155.80M | 181.10M | 170.60M | 172.30M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.25B | 1.04B | 868.00M | 1.54B |
Gain or loss from assets sale | - | - | - | - |